Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

Articles published in
Antimicrob Agents Chemother
    April 2024
  1. CHESNOKOV A, Ivashchenko AA, Matsuzaki Y, Takashita E, et al
    Influenza C virus susceptibility to antivirals with different mechanisms of action.
    Antimicrob Agents Chemother. 2024 Apr 8:e0172723. doi: 10.1128/aac.01727.
    >> Share

  2. XU S, Esmaeili S, Cardozo-Ojeda EF, Goyal A, et al
    Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents.
    Antimicrob Agents Chemother. 2024;68:e0101523.
    >> Share

  3. TANG W-F, Chang Y-H, Lin C-C, Jheng J-R, et al
    BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Antimicrob Agents Chemother. 2024;68:e0095623.
    >> Share

    March 2024
  4. YU Y, Chen S, Zhang H, Duan Y, et al
    A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection.
    Antimicrob Agents Chemother. 2024 Mar 12:e0135023. doi: 10.1128/aac.01350.
    >> Share

  5. MIAH M, Davis AM, Hannoun C, Said JS, et al
    Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.
    Antimicrob Agents Chemother. 2024;68:e0106423.
    >> Share

  6. ZHANG R, Zhou J, Yan H, Liu X, et al
    Manidipine is not a potential inhibitor against SARS-CoV-2 main protease.
    Antimicrob Agents Chemother. 2024;68:e0129723.
    >> Share

    February 2024
  7. PLOTNIK D, Sager JE, Aryal M, Fanget MC, et al
    A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
    Antimicrob Agents Chemother. 2024 Feb 20:e0127323. doi: 10.1128/aac.01273.
    >> Share

    January 2024
  8. YANG H, Yu X, Hou W, Liu X, et al
    Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
    Antimicrob Agents Chemother. 2024 Jan 30:e0138423. doi: 10.1128/aac.01384.
    >> Share

  9. BAKER J, Ombredane H, Daly L, Knowles I, et al
    Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice.
    Antimicrob Agents Chemother. 2024;68:e0105023.
    >> Share

  10. STRIZKI JM, Gaspar JM, Howe JA, Hutchins B, et al
    Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Antimicrob Agents Chemother. 2024;68:e0095323.
    >> Share

    December 2023
  11. ZHANG H, Zhou J, Chen H, Mao J, et al
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    >> Share

    November 2023
  12. TONG X, Keung W, Arnold LD, Stevens LJ, et al
    Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
    Antimicrob Agents Chemother. 2023;67:e0084023.
    >> Share

    July 2023
  13. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Ferris M, et al
    Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
    Antimicrob Agents Chemother. 2023;67:e0026623.
    >> Share

    April 2023
  14. DE LEON P, Canas-Arranz R, Bustos MJ, Saiz M, et al
    Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.
    Antimicrob Agents Chemother. 2023;67:e0170322.
    >> Share

    March 2023
  15. ZHANG D, Zhao Y, You X, He S, et al
    Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection.
    Antimicrob Agents Chemother. 2023;67:e0148722.
    >> Share

  16. LIU STH, Mirceta M, Lin G, Anderson DM, et al
    Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.
    Antimicrob Agents Chemother. 2023;67:e0151422.
    >> Share

    February 2023
  17. GARCIA A, Huh EY, Lee SC
    Serine/Threonine Phosphatase Calcineurin Orchestrates the Intrinsic Resistance to Micafungin in the Human-Pathogenic Fungus Mucor circinelloides.
    Antimicrob Agents Chemother. 2023;67:e0068622.
    >> Share

    January 2023
  18. SOMOVILLA P, Garcia-Crespo C, Martinez-Gonzalez B, Soria ME, et al
    Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin.
    Antimicrob Agents Chemother. 2023;67:e0131522.
    >> Share

  19. ZUMBRUN EE, Kaku CI, Dillinger L, Zak SE, et al
    Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19.
    Antimicrob Agents Chemother. 2023;67:e0135322.
    >> Share

  20. KIM YS, Jeon SH, Kim J, Koh JH, et al
    A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.
    Antimicrob Agents Chemother. 2023;67:e0045222.
    >> Share

    December 2022
  21. KIM TY, Jeon S, Ko M, Du YE, et al
    Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern.
    Antimicrob Agents Chemother. 2022;66:e0120122.
    >> Share

  22. SAKE SM, Kosch C, Blockus S, Haid S, et al
    Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages.
    Antimicrob Agents Chemother. 2022;66:e0103222.
    >> Share

    October 2022
  23. LINGSCHEID T, Kinzig M, Kruger A, Muller N, et al
    Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Antimicrob Agents Chemother. 2022 Oct 26:e0122922. doi: 10.1128/aac.01229.
    >> Share

  24. MUKAE H, Yotsuyanagi H, Ohmagari N, Doi Y, et al
    A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
    Antimicrob Agents Chemother. 2022;66:e0069722.
    >> Share

  25. SHIMIZU R, Sonoyama T, Fukuhara T, Kuwata A, et al
    Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Antimicrob Agents Chemother. 2022;66:e0063222.
    >> Share

  26. RAMBACH G, Striednig B, Neurauter M, Hermann M, et al
    Indications that the Antimycotic Drug Amphotericin B Enhances the Impact of Platelets on Aspergillus.
    Antimicrob Agents Chemother. 2022 Oct 3:e0068122. doi: 10.1128/aac.00681.
    >> Share

    August 2022
  27. LAPAILLERIE D, Charlier C, Guyonnet-Duperat V, Murigneux E, et al
    Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
    Antimicrob Agents Chemother. 2022;66:e0008322.
    >> Share

    July 2022
  28. RODVOLD KA, Gotfried MH, Gupta V, Ek A, et al
    Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.
    Antimicrob Agents Chemother. 2022;66:e0059022.
    >> Share

  29. WATSON JA, Kissler SM, Day NPJ, Grad YH, et al
    Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies.
    Antimicrob Agents Chemother. 2022;66:e0019222.
    >> Share

  30. CHECKMAHOMED L, Carbonneau J, Du Pont V, Riola NC, et al
    In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022;66:e0019822.
    >> Share

  31. ICHO S, Rujas E, Muthuraman K, Tam J, et al
    Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
    Antimicrob Agents Chemother. 2022;66:e0043922.
    >> Share

  32. ATMAR RL, Finch N
    New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2022 Jul 12:e0240421. doi: 10.1128/aac.02404.
    >> Share

    June 2022
  33. LEEGWATER E, Moes DJAR, Bosma LBE, Ottens TH, et al
    Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
    Antimicrob Agents Chemother. 2022;66:e0025422.
    >> Share

  34. PITTS J, Li J, Perry JK, Du Pont V, et al
    Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Antimicrob Agents Chemother. 2022;66:e0022222.
    >> Share

    March 2022
  35. DONG R, Jiang L, Yang T, Wang C, et al
    Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.
    Antimicrob Agents Chemother. 2022;66:e0204521.
    >> Share

  36. CHEN J, Dai L, Kendrick S, Post SR, et al
    The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways.
    Antimicrob Agents Chemother. 2022;66:e0239521.
    >> Share

  37. PARK AYJ, Tran DQ, Schaal JB, Wang M, et al
    Preclinical Pharmacokinetics and Safety of Intravenous RTD-1.
    Antimicrob Agents Chemother. 2022;66:e0212521.
    >> Share

  38. BAGHDADI J, Bejo S, Harris A
    Reply to Casalini et al., "Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution".
    Antimicrob Agents Chemother. 2022;66:e0233221.
    >> Share

  39. CASALINI G, Pozza G, Giacomelli A, Antinori S, et al
    Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution.
    Antimicrob Agents Chemother. 2022;66:e0229621.
    >> Share

  40. HICKERSON BT, Adams SE, Barman S, Miller L, et al
    Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.
    Antimicrob Agents Chemother. 2022 Mar 9:e0000922. doi: 10.1128/aac.00009.
    >> Share

    February 2022
  41. MERCHANTE N, Carcel S, Garrido-Gracia JC, Trigo-Rodriguez M, et al
    Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.
    Antimicrob Agents Chemother. 2022;66:e0210721.
    >> Share

  42. MEUNIER T, Desmarets L, Bordage S, Bamba M, et al
    A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses.
    Antimicrob Agents Chemother. 2022;66:e0158121.
    >> Share

    January 2022
  43. DINESH KUMAR N, Ter Ellen BM, Bouma EM, Troost B, et al
    Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells.
    Antimicrob Agents Chemother. 2022;66:e0154321.
    >> Share

    November 2021
  44. TIETJEN I, Cassel J, Register ET, Zhou XY, et al
    The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants.
    Antimicrob Agents Chemother. 2021;65:e0077221.
    >> Share

    October 2021
  45. BAGHDADI JD, Coffey KC, Adediran T, Goodman KE, et al
    Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.
    Antimicrob Agents Chemother. 2021;65:e0134121.
    >> Share

  46. LI Y, Qi L, Bai H, Sun C, et al
    Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
    Antimicrob Agents Chemother. 2021;65:e0106321.
    >> Share

    September 2021
  47. SCHOOLEY RT, Carlin AF, Beadle JR, Valiaeva N, et al
    Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
    Antimicrob Agents Chemother. 2021;65:e0115521.
    >> Share

  48. SHAH S, Ackley TW, Topal JE
    Renal and Hepatic Toxicity Analysis of Remdesivir Formulations: Does What Is on the Inside Really Count?
    Antimicrob Agents Chemother. 2021;65:e0104521.
    >> Share

  49. YAN VC, Muller FL
    Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.
    Antimicrob Agents Chemother. 2021;65:e0111721.
    >> Share

    August 2021
  50. PASCUA PNQ, Jones JC, Marathe BM, Seiler P, et al
    Baloxavir treatment delays influenza B virus transmission in ferrets and results in limited generation of drug-resistant variants.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0113721. doi: 10.1128/AAC.01137.
    >> Share

  51. GABORIT B, Dailly E, Vanhove B, Josien R, et al
    Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
    Antimicrob Agents Chemother. 2021;65:e0123721.
    >> Share

  52. LI R, Liclican A, Xu Y, Pitts J, et al
    Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells.
    Antimicrob Agents Chemother. 2021;65:e0060221.
    >> Share

  53. GAMMELTOFT KA, Zhou Y, Duarte Hernandez CR, Galli A, et al
    Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0268020.
    >> Share

  54. HANSON BM, Dinh AQ, Tran TT, Arenas S, et al
    Candida auris Invasive Infections During a COVID-19 Case Surge.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0114621. doi: 10.1128/AAC.01146.
    >> Share

    July 2021
  55. GOMIS-FONT MA, Pitart C, Del Barrio-Tofino E, Zboromyrska Y, et al
    Emergence of Resistance to Novel Cephalosporin-beta-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
    Antimicrob Agents Chemother. 2021;65:e0008921.
    >> Share

  56. LIMONTA D, Dyna-Dagman L, Branton W, Mancinelli V, et al
    Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65:e0049121.
    >> Share

  57. WU X, Li N, Wang G, Liu W, et al
    Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Antimicrob Agents Chemother. 2021;65:e0035021.
    >> Share

    June 2021
  58. MANTLO EK, Paessler S, Seregin A, Mitchell A, et al
    Luminore CopperTouch Surface Coating Effectively Inactivates SARS-CoV-2, Ebola Virus, and Marburg Virus In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0139020.
    >> Share

  59. RAMIREZ S, Fernandez-Antunez C, Galli A, Underwood A, et al
    Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
    Antimicrob Agents Chemother. 2021;65:e0009721.
    >> Share

    May 2021
  60. WANG L, Zhu Q, Xiang K, Zhang Y, et al
    Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

    March 2021
  61. MENGUAL-CHULIA B, Alonso-Cordero A, Cano L, Del Mar Mosquera M, et al
    Surveillance of Influenza A resistance to polymerase complex inhibitors by whole genome analysis, 2016-17, 2017-18 and 2018-19 Seasons, Eastern Spain.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.02718.
    >> Share

  62. YAN VC, Muller FL
    Remdesivir for COVID-19: Why Not Dose Higher?
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  63. DORGHAM K, Neumann AU, Decavele M, Luyt CE, et al
    Considering Personalized Interferon Beta Therapy for COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  64. JUNEJA K, Humeniuk R, Porter D, Cao H, et al
    Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?"
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  65. DAVOUDI-MONFARED E, Khalili H
    Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  66. GOOD SS, Westover J, Jung KH, Zhou XJ, et al
    AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  67. KUO CJ, Chao TL, Kao HC, Tsai YM, et al
    Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  68. MAY M, Chang M, Dietz D, Shoucri S, et al
    Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  69. TOMITA Y, Takeda M, Matsuyama S
    The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
    Antimicrob Agents Chemother. 2021 Mar 1. pii: AAC.00020.
    >> Share

    February 2021
  70. KORMAN TM
    Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  71. HOLLAND TL
    Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  72. TE VELTHUIS AJW, Zubkova TG, Shaw M, Mehle A, et al
    Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02605.
    >> Share

  73. MARTINEZ MA
    Plitidepsin: a repurposed drug for the treatment of COVID-19.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.00200.
    >> Share

    January 2021
  74. XU Y, Barauskas O, Kim C, Babusis D, et al
    Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  75. ACKLEY TW, McManus D, Topal JE, Cicali B, et al
    A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

    December 2020
  76. ALEISSA MM, Silverman EA, Paredes Acosta LM, Nutt CT, et al
    New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
    Antimicrob Agents Chemother. 2020;65.
    >> Share

  77. VANDERLINDEN E, Van Winkel N, Naesens L, Van Damme EJM, et al
    In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA and UDA as Inhibitors of Influenza a and B Virus Replication.
    Antimicrob Agents Chemother. 2020 Dec 7. pii: AAC.01732.
    >> Share

    November 2020
  78. SUZUKI S, Nguyen CT, Ogata-Nakahara A, Shibata A, et al
    Efficacy of a cap-dependent endonuclease inhibitor and neuraminidase inhibitors against H7N9 highly pathogenic avian influenza virus causing severe viral pneumonia in cynomolgus macaques.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01825.
    >> Share

  79. MCCULLOUGH PA
    Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  80. YAN VC, Muller FL
    Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  81. LE MP, Le Beller C, Le Hingrat Q, Jaquet P, et al
    Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  82. DOI Y, Hibino M, Hase R, Yamamoto M, et al
    A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

    October 2020
  83. LE MP, Le Hingrat Q, Jaquet P, Wicky PH, et al
    Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  84. BUEHRLE DJ, Decker BK, Wagener MM, Adalja A, et al
    Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

    August 2020
  85. FINTELMAN-RODRIGUES N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, et al
    Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
    Antimicrob Agents Chemother. 2020 Aug 5. pii: AAC.00825.
    >> Share

    January 2020
  86. BROADBENT L, Parke HG, Ferguson LJ, Millar A, et al
    Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  87. DEVINCENZO J, Tait D, Efthimiou J, Mori J, et al
    A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    Antimicrob Agents Chemother. 2020;64.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016